AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018
Apr 24, 2018
32254_dirs_2018-04-24_41601d36-4b53-4d14-9517-596fb05bf26c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-04-20
Reporting Person: Mazzo David J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-04-20 | Common Stock | M | 120000 | $1.13 | Acquired | 120500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-04-20 | Employee Stock Option (right to buy) | $1.13 | M | 120000 | Disposed | 2018-11-18 | Common Stock (120000) | Direct |
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7